← All trials
NCT06902740
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2025
- Primary completion
- Dec 31, 2027
- Completion date
- Dec 31, 2028
- First posted
- Mar 30, 2025
- Last posted
- Aug 7, 2025
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Fudan UniversityCollaborator
- Liaocheng People's HospitalCollaborator
- Chongqing Medical UniversityCollaborator
- Zhengzhou UniversityCollaborator
- Jining NO.1 People 's HospitalCollaborator
- Tangshan Worker's HospitalCollaborator
- Hebei UniversityCollaborator
- Harbin Medical UniversityCollaborator
- Weifang People's HospitalCollaborator
- Xiamen UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Nanjing Medical UniversityCollaborator
- Cangzhou Hospital of Integrated Traditional Chinese and Western MedicineCollaborator
- Baotou Medical UniversityCollaborator
- Chinese Academy of Medical SciencesSponsor investigator
- Shiyan Taihe HospitalCollaborator
- Qingdao UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.